Emerging Role of Non-collagenous Bone Proteins as Osteokines in Extraosseous Tissues


如何引用文章

全文:

详细

Bone is a unique tissue, composed of various types of cells embedded in a calcified extracellular matrix (ECM), whose dynamic structure consists of organic and inorganic compounds produced by bone cells. The main inorganic component is represented by hydroxyapatite, whilst the organic ECM is primarily made up of type I collagen and non-collagenous proteins. These proteins play an important role in bone homeostasis, calcium regulation, and maintenance of the hematopoietic niche. Recent advances in bone biology have highlighted the importance of specific bone proteins, named "osteokines", possessing endocrine functions and exerting effects on nonosseous tissues. Accordingly, osteokines have been found to act as growth factors, cell receptors, and adhesion molecules, thus modifying the view of bone from a static tissue fulfilling mobility to an endocrine organ itself. Since bone is involved in a paracrine and endocrine cross-talk with other tissues, a better understanding of bone secretome and the systemic roles of osteokines is expected to provide benefits in multiple topics: such as identification of novel biomarkers and the development of new therapeutic strategies. The present review discusses in detail the known osseous and extraosseous effects of these proteins and the possible respective clinical and therapeutic significance.

作者简介

Kenda Jawich

Department of Biochemistry and Microbiology, Faculty of Pharmacy,, Damascus University

Email: info@benthamscience.net

Rana Hadakie

Department of Biochemistry and Microbiology, Faculty of Pharmacy,, Damascus University

Email: info@benthamscience.net

Souhaib Jamal

Department of Biochemistry and Microbiology, Faculty of Pharmacy,, Damascus University

Email: info@benthamscience.net

Rana Habeeb

Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University

Email: info@benthamscience.net

Sahar Al Fahoum

Department of Biochemistry and Microbiology, Faculty of Pharmacy,, Damascus University

Email: info@benthamscience.net

Alberto Ferlin

Department of Medicine, Unit of Andrology and Reproductive Medicine,, University of Padova

Email: info@benthamscience.net

Luca De Toni

Department of Medicine, Unit of Andrology and Reproductive Medicine,, University of Padova, Padova,

编辑信件的主要联系方式.
Email: info@benthamscience.net

参考

  1. Alcorta-Sevillano, N.; Macías, I.; Rodríguez, C.I.; Infante, A. Crucial role of lamin A/C in the migration and differentiation of MSCs in bone. Cells, 2020, 9(6), 1330. doi: 10.3390/cells9061330 PMID: 32466483
  2. Zhang, R.; Li, B.; Li, H. Extracellular-matrix mechanics regulate the ocular physiological and pathological activities. J. Ophthalmol., 2023, 2023, 1-11. doi: 10.1155/2023/7626920 PMID: 37521908
  3. Capulli, M.; Paone, R.; Rucci, N. Osteoblast and osteocyte: Games without frontiers. Arch. Biochem. Biophys., 2014, 561, 3-12. doi: 10.1016/j.abb.2014.05.003 PMID: 24832390
  4. Hsu, Y.H.; Kiel, D.P. Clinical review: Genome-wide association studies of skeletal phenotypes: What we have learned and where we are headed. J. Clin. Endocrinol. Metab., 2012, 97(10), E1958-E1977. doi: 10.1210/jc.2012-1890 PMID: 22965941
  5. Dallas, S.L.; Prideaux, M.; Bonewald, L.F. The osteocyte: An endocrine cell and more. Endocr. Rev., 2013, 34(5), 658-690. doi: 10.1210/er.2012-1026 PMID: 23612223
  6. Boyce, B.; Yao, Z.; Xing, L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit. Rev. Eukaryot. Gene Expr., 2009, 19(3), 171-180. doi: 10.1615/CritRevEukarGeneExpr.v19.i3.10 PMID: 19883363
  7. Väänänen, K. Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics. Adv. Drug Deliv. Rev., 2005, 57(7), 959-971. doi: 10.1016/j.addr.2004.12.018 PMID: 15876398
  8. Florencio-Silva, R.; Sasso, G.R.S.; Sasso-Cerri, E.; Simões, M.J.; Cerri, P.S. Biology of bone tissue: Structure, function, and factors that influence bone cells. BioMed. Res. Int., 2015, 2015, 1-17. doi: 10.1155/2015/421746 PMID: 26247020
  9. Carvalho, M.S.; Cabral, J.M.S.; da Silva, C.L.; Vashishth, D. Bone matrix non-collagenous proteins in tissue engineering: Creating new bone by mimicking the extracellular matrix. Polymers (Basel), 2021, 13(7), 1095. doi: 10.3390/polym13071095 PMID: 33808184
  10. Lin, X.; Patil, S.; Gao, Y. G.; Qian, A. The bone extracellular matrix in bone formation and regeneration. Front. Pharmacol., 2020, 11 doi: 10.3389/fphar.2020.00757
  11. Mansour, A.; Mezour, M.A.; Badran, Z.; Tamimi, F. Extracellular matrices for bone regeneration: A literature review. Tissue Eng. Part A, 2017, 23(23-24), 1436-1451. doi: 10.1089/ten.tea.2017.0026 PMID: 28562183
  12. Sroga, G.E.; Karim, L.; Colón, W.; Vashishth, D. Biochemical characterization of major bone-matrix proteins using nanoscale-size bone samples and proteomics methodology. Mol. Cell. Proteomics, 2011, 10(9), M110.006718. doi: 10.1074/mcp.M110.006718 PMID: 21606484
  13. Paiva, K.B.S.; Granjeiro, J.M. Matrix metalloproteinases in bone resorption, remodeling, and repair. Prog. Mol. Biol. Transl. Sci., 2017, 148(9), 203-303. doi: 10.1016/bs.pmbts.2017.05.001
  14. Karsenty, G.; Oury, F. Regulation of male fertility by the bone-derived hormone osteocalcin. Mol. Cell. Endocrinol., 2014, 382(1), 521-526. doi: 10.1016/j.mce.2013.10.008 PMID: 24145129
  15. Pin, F.; Bonewald, L.F.; Bonetto, A. Role of myokines and osteokines in cancer cachexia. Exp. Biol. Med. (Maywood), 2021, 246(19), 2118-2127. doi: 10.1177/15353702211009213 PMID: 33899538
  16. Zaidi, M.; Kim, S.M.; Mathew, M.; Korkmaz, F.; Sultana, F.; Miyashita, S.; Gumerova, A.A.; Frolinger, T.; Moldavski, O.; Barak, O.; Pallapati, A.; Rojekar, S.; Caminis, J.; Ginzburg, Y.; Ryu, V.; Davies, T.F.; Lizneva, D.; Rosen, C.J.; Yuen, T. Bone circuitry and interorgan skeletal crosstalk. eLife, 2023, 12, e83142. doi: 10.7554/eLife.83142 PMID: 36656634
  17. Termine, J.D. Non-collagen proteins in bone. Ciba Found. Symp., 1988, 136, 178-202. doi: 10.1002/9780470513637.ch12 PMID: 3068009
  18. Retting, K.N.; Lyons, K.M. BMPs in Development. Handbook of Cell Signaling, 2nd ed.; Bradshaw, R.A.; Dennis, E.A., Eds.; Academic Press: San Diego, 2010, pp. 1905-1912.
  19. Kirby, D.J.; Young, M.F. Isolation, production, and analysis of small leucine-rich proteoglycans in bone. Methods Cell Biol., 2018, 143, 281-296. doi: 10.1016/bs.mcb.2017.08.016
  20. Moorehead, C.; Prudnikova, K.; Marcolongo, M. The regulatory effects of proteoglycans on collagen fibrillogenesis and morphology investigated using biomimetic proteoglycans. J. Struct. Biol., 2019, 206(2), 204-215. doi: 10.1016/j.jsb.2019.03.005 PMID: 30885681
  21. Kadler, K.E.; Hill, A.; Canty-Laird, E.G. Collagen fibrillogenesis: Fibronectin, integrins, and minor collagens as organizers and nucleators. Curr. Opin. Cell Biol., 2008, 20(5), 495-501. doi: 10.1016/j.ceb.2008.06.008 PMID: 18640274
  22. Corsi, A.; Xu, T.; Chen, X-D.; Boyde, A.; Liang, J.; Mankani, M.; Sommer, B.; Iozzo, R.V.; Eichstetter, I.; Robey, P.G.; Bianco, P.; Young, M.F. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res., 2002, 17(7), 1180-1189. doi: 10.1359/jbmr.2002.17.7.1180 PMID: 12102052
  23. Danziger, J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin. J. Am. Soc. Nephrol., 2008, 3(5), 1504-1510. doi: 10.2215/CJN.00770208 PMID: 18495950
  24. Berkner, K.L.; Runge, K.W. Vitamin K-dependent protein activation: Normal gamma-glutamyl carboxylation and disruption in disease. Int. J. Mol. Sci., 2022, 23(10), 5759. doi: 10.3390/ijms23105759 PMID: 35628569
  25. Laizé, V.; Martel, P.; Viegas, C.S.B.; Price, P.A.; Cancela, M.L. Evolution of matrix and bone γ-carboxyglutamic acid proteins in vertebrates. J. Biol. Chem., 2005, 280(29), 26659-26668. doi: 10.1074/jbc.M500257200 PMID: 15849363
  26. Hauschka, P.V.; Lian, J.B.; Cole, D.E.; Gundberg, C.M. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiol. Rev., 1989, 69(3), 990-1047. doi: 10.1152/physrev.1989.69.3.990 PMID: 2664828
  27. Grzesik, W.J.; Robey, P.G. Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res., 1994, 9(4), 487-496. doi: 10.1002/jbmr.5650090408 PMID: 7518179
  28. Robey, P.G. Bone Matrix Proteoglycans and Glycoproteins. Principles of Bone Biology, 2nd ed.; Academic Press: Cambridge, Massachusetts, 2002, pp. 225-237. doi: 10.1016/B978-012098652-1/50116-5
  29. Ru, D.W.; Yan, Y.F.; Li, B.; Xie, Q.; Tang, R.; Shen, X.; Yu, G.; Du, J.R.; Wang, E.S. Tetranectin knock-out mice exhibit features of kyphosis and osteoporosis. Fudan Univ. J. Med. Sci., 2016, 43(2) doi: 10.3969/j.issn.1672-8467.2016.02.006
  30. Bellahcène, A.; Castronovo, V.; Ogbureke, K.U.E.; Fisher, L.W.; Fedarko, N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat. Rev. Cancer, 2008, 8(3), 212-226. doi: 10.1038/nrc2345 PMID: 18292776
  31. Harris, S.E.; Gluhak-Heinrich, J.; Harris, M.A.; Yang, W.; Bonewald, L.F.; Riha, D.; Rowe, P.S.; Robling, A.G.; Turner, C.H.; Feng, J.Q.; McKee, M.D.; Nicollela, D. DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: Theoretical role in controlling mineral quality in the perilacunar matrix. J. Musculoskelet. Neuronal Interact., 2007, 7(4), 313-315. PMID: 18094489
  32. Bragdon, B.; Moseychuk, O.; Saldanha, S.; King, D.; Julian, J.; Nohe, A. Bone morphogenetic proteins: A critical review. Cell. Signal., 2011, 23(4), 609-620. doi: 10.1016/j.cellsig.2010.10.003 PMID: 20959140
  33. Katagiri, T.; Watabe, T. Bone morphogenetic proteins. Cold Spring Harb. Perspect. Biol., 2016, 8(6), a021899. doi: 10.1101/cshperspect.a021899 PMID: 27252362
  34. Hyzy, S.L.; Olivares-Navarrete, R.; Schwartz, Z.; Boyan, B.D. BMP2 induces osteoblast apoptosis in a maturation state and noggin-dependent manner. J. Cell. Biochem., 2012, 113(10), 3236-3245. doi: 10.1002/jcb.24201 PMID: 22628200
  35. Lombardi, G.; Perego, S.; Luzi, L.; Banfi, G. A four-season molecule: Osteocalcin. Updates in its physiological roles. Endocrine, 2015, 48(2), 394-404. doi: 10.1007/s12020-014-0401-0 PMID: 25158976
  36. De Toni, L.; Jawich, K.; De Rocco, P.M.; Di Nisio, A.; Foresta, C. Osteocalcin: A protein hormone connecting metabolism, bone and testis function. Protein Pept. Lett., 2020, 27(12), 1268-1275. doi: 10.2174/0929866527666200505220459 PMID: 32370705
  37. Lee, N.K.; Sowa, H.; Hinoi, E.; Ferron, M.; Ahn, J.D.; Confavreux, C.; Dacquin, R.; Mee, P.J.; McKee, M.D.; Jung, D.Y.; Zhang, Z.; Kim, J.K.; Mauvais-Jarvis, F.; Ducy, P.; Karsenty, G. Endocrine regulation of energy metabolism by the skeleton. Cell, 2007, 130(3), 456-469. doi: 10.1016/j.cell.2007.05.047 PMID: 17693256
  38. Komori, T. What is the function of osteocalcin? J Oral Biosci., 2020, 62(3), 223-227. doi: 10.1016/j.job.2020.05.004
  39. Wei, J.; Hanna, T.; Suda, N.; Karsenty, G.; Ducy, P. Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a. Diabetes, 2014, 63(3), 1021-1031. doi: 10.2337/db13-0887 PMID: 24009262
  40. Ferron, M.; Wei, J.; Yoshizawa, T.; Del Fattore, A.; DePinho, R.A.; Teti, A.; Ducy, P.; Karsenty, G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell, 2010, 142(2), 296-308. doi: 10.1016/j.cell.2010.06.003 PMID: 20655470
  41. De Toni, L.; Di Nisio, A.; Rocca, M.S.; De Rocco Ponce, M.; Ferlin, A.; Foresta, C. Osteocalcin, a bone-derived hormone with important andrological implications. Andrology, 2017, 5(4), 664-670. doi: 10.1111/andr.12359 PMID: 28395130
  42. Pi, M.; Quarles, L.D. Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology, 2012, 153(5), 2062-2069. doi: 10.1210/en.2011-2117 PMID: 22374969
  43. Karsenty, G. Update on the Biology of Osteocalcin. Endocr. Pract., 2017, 23(10), 1270-1274. doi: 10.4158/EP171966.RA PMID: 28704102
  44. Hinoi, E. Pivotal role of skeletal tissues in the regulation mechanisms for physiological functions mediated by multiple organ networks. Yakugaku Zasshi, 2012, 132(6), 721-725. doi: 10.1248/yakushi.132.721 PMID: 22687731
  45. Ferron, M.; McKee, M.D.; Levine, R.L.; Ducy, P.; Karsenty, G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone, 2012, 50(2), 568-575. doi: 10.1016/j.bone.2011.04.017 PMID: 21550430
  46. Karsenty, G.; Mera, P. Molecular bases of the crosstalk between bone and muscle. Bone, 2018, 115, 43-49. doi: 10.1016/j.bone.2017.04.006 PMID: 28428077
  47. Jawich, K.; Rocca, M.S.; Al Fahoum, S.; Alhalabi, M.; Di Nisio, A.; Foresta, C.; Ferlin, A.; De Toni, L. RS 2247911 polymorphism of GPRC6A gene and serum undercarboxylated-osteocalcin are associated with testis function. J. Endocrinol. Invest., 2022, 45(9), 1673-1682. doi: 10.1007/s40618-022-01803-9 PMID: 35482214
  48. Oury, F.; Sumara, G.; Sumara, O.; Ferron, M.; Chang, H.; Smith, C.E.; Hermo, L.; Suarez, S.; Roth, B.L.; Ducy, P.; Karsenty, G. Endocrine regulation of male fertility by the skeleton. Cell, 2011, 144(5), 796-809. doi: 10.1016/j.cell.2011.02.004 PMID: 21333348
  49. Pi, M.; Kapoor, K.; Ye, R.; Hwang, D.J.; Miller, D.D.; Smith, J.C.; Baudry, J.; Quarles, L.D. Computationally identified novel agonists for GPRC6A. PLoS One, 2018, 13(4), e0195980. doi: 10.1371/journal.pone.0195980 PMID: 29684031
  50. Pi, M.; Kapoor, K.; Ye, R.; Smith, J.C.; Baudry, J.; Quarles, L.D. GPCR6A is a molecular target for the natural products gallate and EGCG in green tea. Mol. Nutr. Food Res., 2018, 62(8), 1700770. doi: 10.1002/mnfr.201700770 PMID: 29468843
  51. Oury, F.; Khrimian, L.; Denny, C.A.; Gardin, A.; Chamouni, A.; Goeden, N.; Huang, Y.; Lee, H.; Srinivas, P.; Gao, X.B.; Suyama, S.; Langer, T.; Mann, J.J.; Horvath, T.L.; Bonnin, A.; Karsenty, G. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell, 2013, 155(1), 228-241. doi: 10.1016/j.cell.2013.08.042 PMID: 24074871
  52. Shan, C.; Ghosh, A.; Guo, X.; Wang, S.; Hou, Y.; Li, S.; Liu, J. Roles for osteocalcin in brain signalling: Implications in cognition- and motor-related disorders. Mol. Brain, 2019, 12(1), 23. doi: 10.1186/s13041-019-0444-5 PMID: 30909971
  53. Khrimian, L.; Obri, A.; Ramos-Brossier, M.; Rousseaud, A.; Moriceau, S.; Nicot, A.S.; Mera, P.; Kosmidis, S.; Karnavas, T.; Saudou, F.; Gao, X.B.; Oury, F.; Kandel, E.; Karsenty, G. Gpr158 mediates osteocalcin’s regulation of cognition. J. Exp. Med., 2017, 214(10), 2859-2873. doi: 10.1084/jem.20171320 PMID: 28851741
  54. Price, P.A.; Fraser, J.D.; Metz-Virca, G. Molecular cloning of matrix Gla protein: Implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. Proc. Natl. Acad. Sci. USA, 1987, 84(23), 8335-8339. doi: 10.1073/pnas.84.23.8335 PMID: 3317405
  55. Schurgers, L.J.; Spronk, H.M.H.; Skepper, J.N.; Hackeng, T.M.; Shanahan, C.M.; Vermeer, C.; Weissberg, P.L.; Proudfoot, D. Post-translational modifications regulate matrix Gla protein function: Importance for inhibition of vascular smooth muscle cell calcification. J. Thromb. Haemost., 2007, 5(12), 2503-2511. doi: 10.1111/j.1538-7836.2007.02758.x PMID: 17848178
  56. Zhang, J.; Ma, Z.; Yan, K.; Wang, Y.; Yang, Y.; Wu, X. Matrix gla protein promotes the bone formation by up-regulating Wnt/β-catenin signaling pathway. Front. Endocrinol. (Lausanne), 2019, 10, 891. doi: 10.3389/fendo.2019.00891 PMID: 31920993
  57. Bjørklund, G.; Svanberg, E.; Dadar, M.; Card, D.J.; Chirumbolo, S.; Harrington, D.J.; Aaseth, J. The role of matrix gla protein (MGP) in vascular calcification. Curr. Med. Chem., 2020, 27(10), 1647-1660. doi: 10.2174/0929867325666180716104159 PMID: 30009696
  58. Borrás, T.; Smith, M.H.; Buie, L.K. A novel Mgp -cre knock-in mouse reveals an anticalcification/antistiffness candidate gene in the trabecular meshwork and peripapillary scleral region. Invest. Ophthalmol. Vis. Sci., 2015, 56(4), 2203-2214. doi: 10.1167/iovs.15-16460 PMID: 25711639
  59. Willems, B.A.G.; Vermeer, C.; Reutelingsperger, C.P.M.; Schurgers, L.J. The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. Mol. Nutr. Food Res., 2014, 58(8), 1620-1635. doi: 10.1002/mnfr.201300743 PMID: 24668744
  60. Yao, Y.; Nowak, S.; Yochelis, A.; Garfinkel, A.; Boström, K.I. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J. Biol. Chem., 2007, 282(41), 30131-30142. doi: 10.1074/jbc.M704297200 PMID: 17670744
  61. Barrett, H.; O’Keeffe, M.; Kavanagh, E.; Walsh, M.; O’Connor, E. Is matrix gla protein associated with vascular calcification? A systematic review. Nutrients, 2018, 10(4), 415. doi: 10.3390/nu10040415 PMID: 29584693
  62. Merle, B.; Garnero, P. The multiple facets of periostin in bone metabolism. Osteoporos. Int., 2012, 23(4), 1199-1212. doi: 10.1007/s00198-011-1892-7 PMID: 22310955
  63. Kudo, A. Periostin in bone biology. Adv. Exp. Med. Biol., 2019, 1132, 43-47. doi: 10.1007/978-981-13-6657-4_5
  64. Maruhashi, T.; Kii, I.; Saito, M.; Kudo, A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. J. Biol. Chem., 2010, 285(17), 13294-13303. doi: 10.1074/jbc.M109.088864 PMID: 20181949
  65. Wang, Z.; An, J.; Zhu, D.; Chen, H.; Lin, A.; Kang, J.; Liu, W.; Kang, X. Periostin: An emerging activator of multiple signaling pathways. J. Cell Commun. Signal., 2022, 16(4), 515-530. doi: 10.1007/s12079-022-00674-2 PMID: 35412260
  66. Yue, H.; Li, W.; Chen, R.; Wang, J.; Lu, X.; Li, J. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. Gynecol. Oncol., 2021, 160(2), 530-538. doi: 10.1016/j.ygyno.2020.11.026 PMID: 33317907
  67. Ma, H.; Wang, J.; Zhao, X.; Wu, T.; Huang, Z.; Chen, D.; Liu, Y.; Ouyang, G. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src pathway-mediated YAP/TAZ activation. Cell Rep., 2020, 30(3), 793-806.e6. doi: 10.1016/j.celrep.2019.12.075 PMID: 31968254
  68. Rosset, E.M.; Bradshaw, A.D. SPARC/osteonectin in mineralized tissue. Matrix Biol., 2016, 52-54, 78-87. doi: 10.1016/j.matbio.2016.02.001 PMID: 26851678
  69. Rossi, M.K.; Gnanamony, M.; Gondi, C.S. The ‘SPARC’ of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer. Int. J. Oncol., 2016, 48(5), 1765-1771. doi: 10.3892/ijo.2016.3417 PMID: 26983777
  70. Mansergh, F.C.; Wells, T.; Elford, C.; Evans, S.L.; Perry, M.J.; Evans, M.J.; Evans, B.A.J. Osteopenia in Sparc (osteonectin)-deficient mice: Characterization of phenotypic determinants of femoral strength and changes in gene expression. Physiol. Genomics, 2007, 32(1), 64-73. doi: 10.1152/physiolgenomics.00151.2007 PMID: 17878319
  71. Guweidhi, A.; Kleeff, J.; Adwan, H.; Giese, N.A.; Wente, M.N.; Giese, T.; Büchler, M.W.; Berger, M.R.; Friess, H. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann. Surg., 2005, 242(2), 224-234. doi: 10.1097/01.sla.0000171866.45848.68 PMID: 16041213
  72. Bradshaw, A.D.; Sage, E.H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J. Clin. Invest., 2001, 107(9), 1049-1054. doi: 10.1172/JCI12939 PMID: 11342565
  73. Hu, J.; Ma, Y.; Ma, J.; Chen, S.; Zhang, X.; Guo, S.; Huang, Z.; Yue, T.; Yang, Y.; Ning, Y.; Zhu, J.; Wang, P.; Wang, X.; Chen, G.; Liu, Y. Macrophage-derived SPARC Attenuates M2-mediated Pro-tumour Phenotypes. J. Cancer, 2020, 11(10), 2981-2992. doi: 10.7150/jca.39651 PMID: 32226513
  74. Lund, S.A.; Giachelli, C.M.; Scatena, M. The role of osteopontin in inflammatory processes. J. Cell Commun. Signal., 2009, 3(3-4), 311-322. doi: 10.1007/s12079-009-0068-0 PMID: 19798593
  75. Wolak, T. Osteopontin – A multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis, 2014, 236(2), 327-337. doi: 10.1016/j.atherosclerosis.2014.07.004 PMID: 25128758
  76. O’Regan, A.; Berman, J.S. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol., 2000, 81(6), 373-390. doi: 10.1046/j.1365-2613.2000.00163.x PMID: 11298186
  77. Scatena, M.; Liaw, L.; Giachelli, C.M. Osteopontin. Arterioscler. Thromb. Vasc. Biol., 2007, 27(11), 2302-2309. doi: 10.1161/ATVBAHA.107.144824 PMID: 17717292
  78. Addison, W.N.; Azari, F.; Sørensen, E.S.; Kaartinen, M.T.; McKee, M.D. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J. Biol. Chem., 2007, 282(21), 15872-15883. doi: 10.1074/jbc.M701116200 PMID: 17383965
  79. Udagawa, N.; Takahashi, N.; Yasuda, H.; Mizuno, A.; Itoh, K.; Ueno, Y.; Shinki, T.; Gillespie, M.T.; Martin, T.J.; Higashio, K.; Suda, T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology, 2000, 141(9), 3478-3484. doi: 10.1210/endo.141.9.7634 PMID: 10965921
  80. Singh, A.; Gill, G.; Kaur, H.; Amhmed, M.; Jakhu, H. Role of osteopontin in bone remodeling and orthodontic tooth movement: A review. Prog. Orthod., 2018, 19(1), 18. doi: 10.1186/s40510-018-0216-2 PMID: 29938297
  81. Gunes, M.; Temizkan, S.; Apaydin, T.; Ilgin, C.; Haklar, G.; Gogas Yavuz, D. Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients. J. Diabetes Complications, 2021, 35(12), 108073. doi: 10.1016/j.jdiacomp.2021.108073 PMID: 34635402
  82. Cook, A.C.; Tuck, A.B.; McCarthy, S.; Turner, J.G.; Irby, R.B.; Bloom, G.C.; Yeatman, T.J.; Chambers, A.F. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol. Carcinog., 2005, 43(4), 225-236. doi: 10.1002/mc.20105 PMID: 15864800
  83. Shevde, L.A.; Samant, R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol., 2014, 37, 131-141. doi: 10.1016/j.matbio.2014.03.001 PMID: 24657887
  84. Robertson, B.W.; Bonsal, L.; Chellaiah, M.A. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol. Cancer, 2010, 9(1), 260. doi: 10.1186/1476-4598-9-260 PMID: 20868520
  85. Kurisetty, V.V.; Johnston, P.G.; Johnston, N.; Erwin, P.; Crowe, P.; Fernig, D.G.; Campbell, F.C.; Anderson, I.P.; Rudland, P.S.; El-Tanani, M.K. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene, 2008, 27(57), 7139-7149. doi: 10.1038/onc.2008.325 PMID: 18794800
  86. Martinez, C.; Churchman, M.; Freeman, T.; Ilyas, M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp. Mol. Pathol., 2010, 88(2), 272-277. doi: 10.1016/j.yexmp.2009.12.008 PMID: 20053348
  87. Amilca-Seba, K.; Sabbah, M.; Larsen, A.K.; Denis, J.A. Osteopontin as a regulator of colorectal cancer progression and its clinical applications. Cancers (Basel), 2021, 13(15), 3793. doi: 10.3390/cancers13153793 PMID: 34359694
  88. Hao, C.; Lane, J.; Jiang, W.G. Osteopontin and cancer: Insights into its role in drug resistance. Biomedicines, 2023, 11(1), 197. doi: 10.3390/biomedicines11010197 PMID: 36672705
  89. Ouyang, X.; Huang, Y.; Jin, X.; Zhao, W.; Hu, T.; Wu, F.; Huang, J. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. OncoTargets Ther., 2018, 11, 5933-5941. doi: 10.2147/OTT.S164007 PMID: 30275702
  90. Aksoy, A.; Artas, G.; Sevindik, O.G. Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer. Pak. J. Med. Sci., 2017, 33(3), 560-565. doi: 10.12669/pjms.333.12559 PMID: 28811771
  91. Lamort, A.S.; Giopanou, I.; Psallidas, I.; Stathopoulos, G.T. Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight. Cells, 2019, 8(8), 815. doi: 10.3390/cells8080815 PMID: 31382483
  92. Kahles, F.; Findeisen, H.M.; Bruemmer, D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol. Metab., 2014, 3(4), 384-393. doi: 10.1016/j.molmet.2014.03.004 PMID: 24944898
  93. Rittling, S.R.; Singh, R. Osteopontin in immune-mediated diseases. J. Dent. Res., 2015, 94(12), 1638-1645. doi: 10.1177/0022034515605270 PMID: 26341976
  94. Santamaría, M.H.; Corral, R.S. Osteopontin-dependent regulation of Th1 and Th17 cytokine responses in Trypanosoma cruzi-infected C57BL/6 mice. Cytokine, 2013, 61(2), 491-498. doi: 10.1016/j.cyto.2012.10.027 PMID: 23199812
  95. Hirano, Y.; Aziz, M.; Yang, W.L.; Wang, Z.; Zhou, M.; Ochani, M.; Khader, A.; Wang, P. Neutralization of osteopontin attenuates neutrophil migration in sepsis-induced acute lung injury. Crit. Care, 2015, 19(1), 53. doi: 10.1186/s13054-015-0782-3 PMID: 25887405
  96. Wesson, J.A.; Johnson, R.J.; Mazzali, M.; Beshensky, A.M.; Stietz, S.; Giachelli, C.; Liaw, L.; Alpers, C.E.; Couser, W.G.; Kleinman, J.G.; Hughes, J. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol., 2003, 14(1), 139-147. doi: 10.1097/01.ASN.0000040593.93815.9D PMID: 12506146
  97. Özkalaycı, F.; Gülmez, Ö.; Uğur-Altun, B.; Pandi-Perumal, S.R.; Altun, A. The role of osteoprotegerin as a cardioprotective versus reactive inflammatory marker: The chicken or the egg paradox. Balkan Med. J., 2018, 35(3), 225-232. doi: 10.4274/balkanmedj.2018.0579 PMID: 29687784
  98. Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Lüthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W.J. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997, 89(2), 309-319. doi: 10.1016/S0092-8674(00)80209-3 PMID: 9108485
  99. Boyce, B.F.; Xing, L. The RANKL/RANK/OPG pathway. Curr. Osteoporos. Rep., 2007, 5(3), 98-104. doi: 10.1007/s11914-007-0024-y PMID: 17925190
  100. Aubin, J.E.; Bonnelye, E. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int., 2000, 11(11), 905-913. doi: 10.1007/s001980070028 PMID: 11193242
  101. Bucay, N.; Sarosi, I.; Dunstan, C.R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H.L.; Xu, W.; Lacey, D.L.; Boyle, W.J.; Simonet, W.S. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev., 1998, 12(9), 1260-1268. doi: 10.1101/gad.12.9.1260 PMID: 9573043
  102. Saidenberg-Kermanac’h, N.; Cohen-Solal, M.; Bessis, N.; De Vernejoul, M.C.; Boissier, M.C. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine, 2004, 71(1), 9-13. doi: 10.1016/S1297-319X(03)00131-3 PMID: 14769514
  103. Akiyama, T.; Shinzawa, M.; Akiyama, N. RANKL-RANK interaction in immune regulatory systems. World J. Orthop., 2012, 3(9), 142-150. doi: 10.5312/wjo.v3.i9.142 PMID: 23173110
  104. Chino, T.; Draves, K.E.; Clark, E.A. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J. Leukoc. Biol., 2009, 86(4), 933-940. doi: 10.1189/jlb.0708419 PMID: 19641036
  105. Di Bartolo, B.A.; Schoppet, M.; Mattar, M.Z.; Rachner, T.D.; Shanahan, C.M.; Kavurma, M.M. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc. Res., 2011, 91(3), 537-545. doi: 10.1093/cvr/cvr084 PMID: 21447702
  106. Wang, Y.; Liu, Y.; Huang, Z.; Chen, X.; Zhang, B. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov., 2022, 8(1), 252. doi: 10.1038/s41420-022-01042-0 PMID: 35523775
  107. Ono, T.; Hayashi, M.; Sasaki, F.; Nakashima, T. RANKL biology: Bone metabolism, the immune system, and beyond. Inflamm. Regen., 2020, 40(1), 2. doi: 10.1186/s41232-019-0111-3 PMID: 32047573
  108. Alsterda, A.; Asha, K.; Powrozek, O.; Repak, M.; Goswami, S.; Dunn, A.M.; Memmel, H.C.; Sharma-Walia, N. Salubrinal exposes anticancer properties in inflammatory breast cancer cells by manipulating the endoplasmic reticulum stress pathway. Front. Oncol., 2021, 11, 654940. doi: 10.3389/fonc.2021.654940 PMID: 34094947
  109. Holen, I.; Shipman, C.M. Role of osteoprotegerin (OPG) in cancer. Clin. Sci. (Lond.), 2006, 110(3), 279-291. doi: 10.1042/CS20050175 PMID: 16464170
  110. Kallioniemi, A. Bone morphogenetic protein 4—a fascinating regulator of cancer cell behavior. Cancer Genet., 2012, 205(6), 267-277. doi: 10.1016/j.cancergen.2012.05.009 PMID: 22749032
  111. Farhadieh, R.D.; Gianoutsos, M.P.; Yu, Y.; Walsh, W.R. The role of bone morphogenetic proteins BMP-2 and BMP-4 and their related postreceptor signaling system (Smads) in distraction osteogenesis of the mandible. J. Craniofac. Surg., 2004, 15(5), 714-718. doi: 10.1097/00001665-200409000-00003 PMID: 15346005
  112. Choi, S.; Yu, J.; Park, A.; Dubon, M.J.; Do, J.; Kim, Y.; Nam, D.; Noh, J.; Park, K.S. BMP-4 enhances epithelial mesenchymal transition and cancer stem cell properties of breast cancer cells via Notch signaling. Sci. Rep., 2019, 9(1), 11724. doi: 10.1038/s41598-019-48190-5 PMID: 31409851
  113. Deng, G.; Chen, Y.; Guo, C.; Yin, L.; Han, Y.; Li, Y.; Fu, Y.; Cai, C.; Shen, H.; Zeng, S. BMP4 promotes the metastasis of gastric cancer by inducing epithelial-mesenchymal transition via Id1. J. Cell Sci., 2020, 133(11), jcs.237222. doi: 10.1242/jcs.237222 PMID: 32376787
  114. Westhrin, M.; Holien, T.; Zahoor, M.; Moen, S.H.; Buene, G.; Størdal, B.; Hella, H.; Yuan, H.; de Bruijn, J.D.; Martens, A.; Groen, R.W.J.; Bosch, F.; Smith, U.; Sponaas, A.M.; Sundan, A.; Standal, T. Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on bone. JBMR Plus, 2020, 4(1), e10247. doi: 10.1002/jbm4.10247 PMID: 31956851
  115. Chiu, C.Y.; Kuo, K.K.; Kuo, T.L.; Lee, K.T.; Cheng, K.H. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration. Mol. Cancer Res., 2012, 10(3), 415-427. doi: 10.1158/1541-7786.MCR-11-0293 PMID: 22241220
  116. Cao, Y.; Tan, Q.; Li, J.; Wang, J. Bone morphogenetic proteins 2, 6, and 9 differentially regulate the osteogenic differentiation of immortalized preodontoblasts. Braz. J. Med. Biol. Res., 2020, 53(9), e9750. doi: 10.1590/1414-431x20209750 PMID: 32756815
  117. Simic, P.; Culej, J.B.; Orlic, I.; Grgurevic, L.; Draca, N.; Spaventi, R.; Vukicevic, S. Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption. J. Biol. Chem., 2006, 281(35), 25509-25521. doi: 10.1074/jbc.M513276200 PMID: 16798745
  118. Dichmann, D.S.; Miller, C.P.; Jensen, J.; Scott Heller, R.; Serup, P. Expression and misexpression of members of the FGF and TGFβ families of growth factors in the developing mouse pancreas. Dev. Dyn., 2003, 226(4), 663-674. doi: 10.1002/dvdy.10270 PMID: 12666204
  119. Pauk, M.; Bordukalo-Niksic, T.; Brkljacic, J.; Paralkar, V.M.; Brault, A.L.; Dumic-Cule, I.; Borovecki, F.; Grgurevic, L.; Vukicevic, S. A novel role of bone morphogenetic protein 6 (BMP6) in glucose homeostasis. Acta Diabetol., 2019, 56(3), 365-371. doi: 10.1007/s00592-018-1265-1 PMID: 30539233
  120. Singla, D.K.; Singla, R.; Wang, J. BMP-7 treatment increases M2 macrophage differentiation and reduces inflammation and plaque formation in Apo E-/- mice. PLoS One, 2016, 11(1), e0147897. doi: 10.1371/journal.pone.0147897 PMID: 26824441
  121. Wang, G.; Han, J.; Wang, S.; Li, P. Expression and purification of recombinant human bone morphogenetic protein-7 in Escherichia coli. Prep. Biochem. Biotechnol., 2014, 44(1), 16-25. doi: 10.1080/10826068.2013.782043 PMID: 24117149
  122. Narasimhulu, C.A.; Singla, D.K. BMP-7 attenuates sarcopenia and adverse muscle remodeling in diabetic mice via alleviation of lipids, inflammation, HMGB1, and pyroptosis. Antioxidants, 2023, 12(2), 331. doi: 10.3390/antiox12020331 PMID: 36829889
  123. Davies, M.R.; Lund, R.J.; Hruska, K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J. Am. Soc. Nephrol., 2003, 14(6), 1559-1567. doi: 10.1097/01.ASN.0000068404.57780.DD PMID: 12761256
  124. Dorai, H.; Sampath, T.K. Bone morphogenetic protein-7 modulates genes that maintain the vascular smooth muscle cell phenotype in culture. J. Bone Joint Surg. Am., 2001, 83(Pt 1)(Suppl. 1), S1-, 70-S1-78. doi: 10.2106/00004623-200100001-00010 PMID: 11263669

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024